Clinical Trials Arena August 6, 2024
The study is supported by a grant from the US Department of Defense and seeks to enhance survival rates.
UCLA Health Jonsson Comprehensive Cancer Center is set to initiate a clinical trial of a personalised cancer vaccine aimed at combating aggressive brain tumours in adolescents and young adults.
The vaccine, developed at UCLA, specifically targets H3 G34-mutant diffuse hemispheric glioma.
It operates by equipping the dendritic cells of the patient to recognise and attack the altered RNA regulation characteristic of this cancer type. These primed dendritic cells are then reintroduced into the patient’s body.
The trial is designed to assess the vaccine’s safety and efficacy in young patients with diffuse hemispheric glioma.
It will initially include patients aged over 18...
Today's Sponsors
Today's Sponsor